Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reiterated by equities researchers at B. Riley in a research note issued to investors on Friday. They currently have a $205.00 price target on the biopharmaceutical company’s stock. B. Riley’s target price would suggest a potential upside of 65.34% from the stock’s current price.
ALNY has been the topic of a number of other reports. Credit Suisse Group boosted their target price on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $14.71 target price (down from $188.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 2nd. Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research note on Friday, December 15th. FBR & Co initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, October 30th. They issued a “buy” rating and a $150.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $152.00 target price (up from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $121.20.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down $1.26 during mid-day trading on Friday, reaching $123.99. 547,200 shares of the company’s stock were exchanged, compared to its average volume of 769,533. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. The company has a market cap of $12,270.00, a P/E ratio of -23.62 and a beta of 2.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. During the same period in the previous year, the company posted ($1.21) earnings per share. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. research analysts predict that Alnylam Pharmaceuticals will post -5.29 earnings per share for the current fiscal year.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total value of $4,089,072.36. Following the sale, the executive vice president now directly owns 45,201 shares in the company, valued at approximately $5,490,113.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael Mason sold 36,745 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now owns 6,352 shares in the company, valued at $835,859.68. The disclosure for this sale can be found here. Insiders sold a total of 274,075 shares of company stock worth $35,356,089 over the last quarter. Corporate insiders own 4.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $800,000. Westpac Banking Corp purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $723,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $165,000. Schwab Charles Investment Management Inc. lifted its stake in Alnylam Pharmaceuticals by 7.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 262,416 shares of the biopharmaceutical company’s stock worth $33,340,000 after purchasing an additional 17,866 shares in the last quarter. Finally, Gulf International Bank UK Ltd purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $3,792,000. Institutional investors and hedge funds own 88.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://transcriptdaily.com/2018/01/19/b-riley-reaffirms-buy-rating-for-alnylam-pharmaceuticals-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.